METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours.

ABSTRACT:

Background

Preclinical studies have suggested that metformin has anti-tumour effects, likely due to blockage of mammalian target of rapamycin pathway through adenosine monophosphate-activated protein kinase and decreased insulin levels. A retrospective study showed that metformin added to everolimus to treat type 2 diabetes mellitus offered longer progression-free survival (PFS) in patients with pancreatic neuroendocrine tumours (NET).

Aims

To evaluate the efficacy and safety of metformin monotherapy in patients with advanced/metastatic well-differentiated NET (WD-NET) of gastroenteropancreatic (GEP) or pulmonary origin.

Patients and methods

Single-arm phase II trial of metformin 850 mg PO twice daily until progression or intolerance for patients with progressive meta

SUBMITTER: Glasberg J 

PROVIDER: S-EPMC9085158 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature